TRIDENT LIFELINE
Back to All Ratios
|
TRIDENT LIFELINE Last 5 Year Core EBITDA Growth History
[Consolidated]
Mar2024 | Mar2023 | Mar2022 | |
---|---|---|---|
Core EBITDA Growth(%) | 38.82 | 124.29 | - |
What is the latest Core EBITDA Growth ratio of TRIDENT LIFELINE ?
Year | Core EBITDA Growth |
---|---|
Mar2024 | 38.82 |
Mar2023 | 124.29 |
Mar2022 | - |
How is Core EBITDA Growth of TRIDENT LIFELINE Trending?
Years | Core EBITDA Growth | % Change | |
---|---|---|---|
Mar2024 | 38.82 | -68.77 | |
Mar2023 | 124.29 | 0 | |
Mar2022 | 0 | - |
Other Financial Ratios of TRIDENT LIFELINE
Operational & Financial Ratios Earnings Per Share CEPS DPS Book NAV/Share Tax Rate | Margin Ratios Core EBITDA Margin EBIT Margin Pre Tax Margin PAT Margin Cash Profit Margin | Performance Ratios ROA ROE ROCE Asset Turnover Sales/Fixed Asset Working Capital/Sales | Efficiency Ratios Fixed Capital/Sales Receivable days Inventory Days Payable days | Valuation Parameters PER PCE Price/Book Yield EV/Net Sales EV/Core EBITDA EV/EBIT EV/CE M Cap / Sales | Growth Ratios Net Sales Growth EBIT Growth PAT Growth EPS Growth | Financial Stability Ratios Total Debt/Equity Current Ratio Quick Ratio Interest Cover Total Debt/Mcap |
Compare Core EBITDA Growth ratio of peers of TRIDENT LIFELINE
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
TRIDENT LIFELINE | ₹286.9 Cr | 4.9% | -4.9% | 33.5% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES | ₹402,213.0 Cr | 4.7% | -5.4% | 0.5% | Stock Analytics | |
DIVIS LABORATORIES | ₹150,403.0 Cr | 0.5% | -9.8% | 55.5% | Stock Analytics | |
CIPLA | ₹117,415.0 Cr | 2% | -1.8% | -1.5% | Stock Analytics | |
TORRENT PHARMACEUTICALS | ₹104,791.0 Cr | 2.6% | -6.1% | 14% | Stock Analytics | |
DR REDDYS LABORATORIES | ₹92,228.2 Cr | -0.9% | -10% | -11.3% | Stock Analytics |
TRIDENT LIFELINE Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
TRIDENT LIFELINE | 4.9% |
-4.9% |
33.5% |
SENSEX | 0.4% |
-4.9% |
-0.1% |
You may also like the below Video Courses